Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Resectable NSCLC × sintilimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 52 Stomach Neoplasms 42 Carcinoma, Non-Small-Cell Lung 30 Colorectal Neoplasms 21 Esophageal Squamous Cell Carcinoma 15 Lung Neoplasms 11 Nasopharyngeal Carcinoma 10 Rectal Neoplasms 9 Esophageal Neoplasms 9 Pancreatic Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6 Small Cell Lung Carcinoma 5 Neoplasms 5 Liver Neoplasms 5 Cholangiocarcinoma 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 4 Carcinoma, Renal Cell 4 Recurrence 3 Neoplasm Metastasis 3 Lymphoma, Extranodal NK-T-Cell 3 Colorectal Cancer Metastatic 3 Colonic Neoplasms 3 Carcinoma 3 Breast Neoplasms 3 Turcot syndrome 2 Thyroid Neoplasms 2 Spinocerebellar Degenerations 2 Sarcoma 2 Nonsquamous Non-Small Cell Lung Cancer 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07492342 2026-03-25

K-NADIR

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting

Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡